An example from the Novartis Malaria Initiative

transcript

Driving access to medicine An example from the Novartis Malaria Initiative Hans Rietveld

Director, Market Access & Capacity Building

Novartis Malaria Initiative

Social Forum - Geneva

February 20, 2015

Efforts by Global Health Community to control and eliminate malaria continue to yield positive results

BUT…

| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine

60 seconds

ONE child in Africa

dies of malaria

60s Every

Progress made 2000–2013

*Source: WHO, World Malaria Report 2014

54% decrease in mortality

rate in Africa

26% decline in

incidence globally

4.3 million

malaria deaths averted

globally

Malaria Initiative Mission and Strategy

Remain the Pharmaceutical leader in efforts contributing to Malaria Elimination

Provide Treatment R&D for novel antimalarials

Ensure Access Build Capacity

INNOVATION & PARTNERSHIP

>700 Million treatments delivered without profit since 2001

72 Million treatments delivered in 2014

.. to 65 malaria

endemic countries

Responding to the unmet medical needs of infants & children

First child-friendly ACT introduced in 2009

– Public-private partnership with Medicines

for Malaria Venture (MMV)

– Meeting the calls from UNICEF and WHO

“to make medicines child-sized”

Helping to reduce child mortality

NIGERIA

> 250 Million pediatric formulations delivered!

Improving patient compliance with Coartem® 80/480, a new treatment with lower pill burden for adult patients

Full adult treatment course

reduced from 24 tablets to 6

tablets

Launch ongoing in malaria

endemic countries in Sub-

Saharan African

| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine 6

Power of One One dollar donated. One child treated

Public fundraising campaign to fund malaria tests and treatments

through online and mobile technology

One dollar donated. One child treated

Novartis matches up to 1 million treatments every year for 3 years

Achieved 3 million treatments for Zambia and closed the malaria

treatment gap

Campaign on-going: www.Po1.org

*US-based charity

Ground-breaking collaboration between Novartis and Malaria No More*

From ‘SMS for Life 1.0’ to ‘SMS for Life 2.0’

From mobile phone to TABLET

Partnering with Lagos State Ministry of Health, Nigeria

A new tablet computer-based ‘SMS for Life’ solution to support:

– Medical stock visibility and reporting

– Disease surveillance

– Health worker training

Capacity building Training, education, and awareness

Provide forum for best practice sharing among National

Malaria Control Program managers and key partners

Best Practice Sharing Workshops

Health Systems Strengthening

Develop innovative tools to improve health workers’

knowledge of malaria case management

Pharmacist Academy to train pharmacists on malaria case

management piloted in Kenya and Nigeria

Public Awareness

Provide educational materials for school children

Accelerating malaria elimination

New drugs with following key properties are needed:

1. Novel mechanisms of action to anticipate emergence of

artemisinin resistance

2. Single dose treatment to improve patient compliance and target

asymptomatic patients

3. Drug that kill gametocytes and prevent parasite transmission

4. Drugs with prophylactic activity

5. P. vivax radical cure to prevent disease relapse

6. Drugs for special populations (pregnant women; G6PD deficiency)

Novartis has a strong pipeline of next generation antimalarial drugs

Transmission Blocking

Potential KAE609

KAF156

Radical Cure PI4K (Imidazopyrazines, Pre-clin)

Prophylaxis KAF156

Single Exposure KAE609

KAF156

Artemisinin Resistance KAE609 (spiroindolone, Ph II)

KAF156 (Imidazolopiperazine, Ph II)

Extensive partnership and collaboration driving industry-leading progress in drug discovery for malaria treatment

NITD in partnership with

academic centers, MMV,

BPRC, WT, and others

Accelerated drug discovery:

High throughput screening to

clinical Proof-of-Concept in

less than 6 years for both

KAE609 and KAF156

Novartis Institute for Tropical Diseases (NITD); Medicines for Malaria Venture (MMV); Biomedical Primate Research Centre (BPRC);

Wellcome Trust (WT); Kenyan Medical Research Institute (KEMRI)

Adequate funding

Potential spread of artemisinin resistance

Accelerating development of new drugs

Malaria diagnostics – access for all patients

Counterfeits & sub-standard antimalarials

Making access more sustainable

......Key Challenges

Increasing access

to products

Broad portfolio:

Ca. 100 drugs included

Selected based on local

disease burden (incl. EMLs)

Ensuring affordability:

Low-cost generics, vaccines,

OTC and Pharma products

Customized packs

for local needs and labeling in

local dialect

Providing education

and services

Health education:

Local health educators present on

prevention, child and maternal

health and symptom awareness

Healthcare Professional

education:

Address limited training

Supply management:

Ensure continuity of supply in

village pharmacies

Provided directly in villages via

health camps

Making an

impact

Improved access to

healthcare across 10 states,

in ca. 30,000 villages, home

to 50 million people

Partnering with thousands of

clinics and pharmacies

More than 300,000 village

health meetings and health

camps conducted, attended

by almost 11 million people

(2010-2014)

Conversion rate 12% (vs 2%

at the outset of the program)

Break-even after 30 months

Pioneering new approaches Arogya Parivar (Healthy Family) in India, started in 2007, break-even after 30 months

14 | Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine

Group Social Business is now operating in new countries

India Since 2007

Vietnam Since Nov 2012

Kenya Since Mar 2012

Indonesia In rollout stage

FTEs 529

People reached 6.6 million

Patients reached 788,000

15 | Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine

....NO ONE should die of malaria today

| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine 16

This presentation was part of the Roundtable on Good practices in promoting access

to medicines during the Social Forum on 20th February, 2015 in Geneva.

Please note that the views and opinions of the speakers do not necessarily reflect

those of Novartis. Novartis only recommends the use of its products in accordance with

the locally approved package insert.

GLEM/COARTEM/0003

An example from the Novartis Malaria Initiative

Documents